TOP GUIDELINES OF ABBV-744 SAFETY AND SIDE EFFECTS

In Phase C, individuals will receive ABBV-744 and oral navitoclax. In Section D, contributors will obtain ABBV-744 and ruxolitinib. Participants will get treatment until sickness progression or even the contributors are unable to tolerate the study drugs.and afterwards market H3K27Ac at this area. Chromatin hyperacetylation could increase the acces